Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
暂无分享,去创建一个
Kenji Matsuno | Masao Ohashi | K. Matsuno | K. Morikawa | N. Huh | M. Yashiro | Tsuyoshi Waku | H. Miyachi | K. Kataoka | T. Oyama | Takuji Oyama | Hiromi Nobusada | Kosuke Morikawa | Hiroyuki Miyachi | Masakazu Yashiro | Endy Widya Putranto | Tsuyoshi Waku | Ken Kataoka | Nam-Ho Huh | M. Ohashi | Hiromi Nobusada
[1] M. Sakaguchi,et al. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. , 2011, Oncology reports.
[2] M. Makishima,et al. Design, synthesis, and evaluation of a novel series of α-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) α/δ dual agonists for the treatment of metabolic syndrome , 2006 .
[3] Paulo C. T. Souza,et al. GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain , 2012, The Journal of Biological Chemistry.
[4] G. Landreth. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.
[5] I. Lu,et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.
[6] E. Breslow,et al. Effect of low pH on neurophysin-peptide interactions: implications for the stability of the amino-carboxylate salt bridge. , 1977, Biochemistry.
[7] Shuichi Hirono,et al. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship. , 2011, Journal of medicinal chemistry.
[8] E. Novellino,et al. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. , 2008, Journal of medicinal chemistry.
[9] Naoyuki Kuwabara,et al. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. , 2012, Journal of medicinal chemistry.
[10] J. Schwabe,et al. Molecular Determinants of the Balance between Co-repressor and Co-activator Recruitment to the Retinoic Acid Receptor* , 2003, Journal of Biological Chemistry.
[11] R. Kaundal,et al. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. , 2010, Drug news & perspectives.
[12] B. Testa,et al. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.
[13] Nanping Wang,et al. Role of Peroxisome Proliferator-Activated Receptor-γ in Atherosclerosis , 2011 .
[14] D. Dubé,et al. REDUCTIVE N-ALKYLATION OF AMIDES, CARBAMATES AND UREAS , 1999 .
[15] K. Mihara,et al. Immortalization of normal human fibroblasts by treatment with 4‐nitroquinoline 1‐oxide , 1993, International journal of cancer.
[16] H P Koeffler,et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.
[17] S. Hirono,et al. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists. , 2011, Bioorganic & medicinal chemistry.
[18] Dae Hwan Kim,et al. Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. , 2009, World journal of gastroenterology.
[19] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[20] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[21] S. Tsujitani,et al. Recent results of therapy for scirrhous gastric cancer , 2009, Surgery Today.
[22] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.
[23] M. Makishima,et al. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. , 2008, Bioorganic & medicinal chemistry letters.
[24] E. Novellino,et al. Insights into the Mechanism of Partial Agonism , 2007, Journal of Biological Chemistry.
[25] Y. Matsuzawa,et al. Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.
[26] M. Makishima,et al. Structure-Based Design and Synthesis of Fluorescent PPARα/δ Co-agonist and Its Application as a Probe for Fluorescent Polarization Assay of PPARδ Ligands , 2008 .
[27] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[28] A. Ross,et al. Malignant gastroenteric obstruction: therapeutic options. , 2007, Gastrointestinal endoscopy clinics of North America.
[29] M. Makishima,et al. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists , 2007 .
[30] W. Wahli,et al. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.
[31] M. Yashiro,et al. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice , 2004, Clinical & Experimental Metastasis.
[32] K. Umesono,et al. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.
[33] J. Lehmann,et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] M. Makishima,et al. Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ-selective partial agonists by disruption of molecular planarity/symmetry. , 2010, Bioorganic & medicinal chemistry.
[35] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[36] B. Spiegelman,et al. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Mendez,et al. PPAR&ggr; Inhibition of Cyclooxygenase-2, PGE2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes , 2003, Hypertension.
[38] R. Evans,et al. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.
[39] Hui Li,et al. Role of Retinoid Receptor Coactivator Pockets in Cofactor Recruitment and Transcriptional Regulation* , 2001, The Journal of Biological Chemistry.
[40] R. Morrison,et al. Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.
[41] T. Okumura,et al. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .
[42] K. Morikawa,et al. The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.
[43] M. Lazar,et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.
[44] Y. Hashimoto,et al. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures , 2009, Acta crystallographica. Section D, Biological crystallography.